Literature DB >> 1576097

The selective bradycardic effects of zatebradine (UL-FS 49) do not adversely affect left ventricular function in conscious pigs with chronic coronary artery occlusion.

L J van Woerkens1, W J van der Giessen, P D Verdouw.   

Abstract

This study was designed to test whether the selective bradycardic effects of zatebradine (UL-FS 49) were altered in the setting of chronic mild left ventricular dysfunction secondary to a myocardial infarction. We therefore administered four doses of UL-FS 49 at 15-min intervals (cumulative doses of 10, 30, 100, and 300 micrograms/kg) to eight normal conscious pigs and to seven pigs in which the left circumflex coronary artery was occluded 3 weeks previously. Left ventricular dysfunction in this second group of animals was manifested by an increase in left ventricular end-diastolic pressure (LVEDP, 11 +/- 2 mmHg vs. 7 +/- 1 mmHg, respectively; p less than 0.05) and a decrease in LVdP/dtmax (3020 +/- 210 mmHg vs. 3720 +/- 210 mmHg, respectively; p less than 0.05). The results showed that UL-FS 49 was equally effective in reducing heart rate in both groups of animals [from 126 +/- 4 to 95 +/- 2 beats/min and from 140 +/- 5 to 98 +/- 6 beats/min for the normal animals and for the animals with a chronic myocardial infarction (MI), respectively]. The duration of left ventricular systole was not affected, but the duration of diastole was prolonged from 290 +/- 10 msec to 420 +/- 20 msec in the normal animals and from 250 +/- 10 msec to 430 +/- 30 msec in the animals with MI (both p less than 0.05). Up to 100 micrograms/kg UL-FS 49 did not affect arterial blood pressure, whereas LVdP/dtmax and cardiac output decreased by less than 10% in either group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576097     DOI: 10.1007/bf00050918

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  19 in total

1.  Specific bradycardic agents, a new therapeutic modality for anesthesiology: hemodynamic effects of UL-FS 49 and propranolol in conscious and isoflurane-anesthetized dogs.

Authors:  D C Riley; G J Gross; J P Kampine; D C Warltier
Journal:  Anesthesiology       Date:  1987-11       Impact factor: 7.892

2.  Effect of tachycardia on regional function and transmural myocardial perfusion during graded coronary pressure reduction in conscious dogs.

Authors:  J M Canty; J Giglia; D Kandath
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

3.  Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure.

Authors:  W J van der Giessen; L J van Woerkens; D J Duncker; J R Roelandt; P D Verdouw
Journal:  J Cardiovasc Pharmacol       Date:  1989-10       Impact factor: 3.105

4.  Decreased incidence of ventricular fibrillation after an acute coronary artery ligation in exercised pigs.

Authors:  M G Scheffer; P D Verdouw
Journal:  Basic Res Cardiol       Date:  1983 May-Jun       Impact factor: 17.165

5.  Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis.

Authors:  B D Guth; G Heusch; R Seitelberger; J Ross
Journal:  Circulation       Date:  1987-03       Impact factor: 29.690

6.  The effects of alinidine, an N-allyl derivative of clonidine, on regional myocardial perfusion and performance in the pig with or without atrial pacing.

Authors:  P D Verdouw; P R Saxena; H C Schamhardt; T M van der Hoek; A M Rutteman
Journal:  Eur J Pharmacol       Date:  1980-06-27       Impact factor: 4.432

7.  Comparison of the haemodynamic effects of the selective bradycardic agent UL-FS 49, with those of propranolol during treadmill exercise in dogs.

Authors:  G Krumpl; M Winkler; W Schneider; G Raberger
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

8.  Changes in systemic haemodynamics, regional myocardial function and perfusion induced by alinidine in pigs with and without narrowed coronary arteries.

Authors:  P D Verdouw; D J Duncker; T J Heere; P R Saxena
Journal:  Eur Heart J       Date:  1987-12       Impact factor: 29.983

9.  Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".

Authors:  W Kobinger; C Lillie
Journal:  Eur J Pharmacol       Date:  1984-09-03       Impact factor: 4.432

10.  Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine.

Authors:  C Indolfi; B D Guth; T Miura; S Miyazaki; R Schulz; J Ross
Journal:  Circulation       Date:  1989-10       Impact factor: 29.690

View more
  5 in total

1.  Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil.

Authors:  L J van Woerkens; N R Baas; W J van der Giessen; P D Verdouw
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

2.  Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

Authors:  C Thollon; C Cambarrat; J Vian; J F Prost; J L Peglion; J P Vilaine
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

3.  Haemodynamic actions of a novel sino-atrial node function modulator, ZENECA ZD7288, in the anaesthetized dog: a comparison with zatebradine, atenolol and nitrendipine.

Authors:  W Rouse; I R Johnson
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

4.  The haemodynamic actions of ZENECA ZD7288, a novel sino-atrial node function modulator, in the exercising beagle: a comparison with zatebradine and propranolol.

Authors:  W Rouse; P J Stafford; I R Johnson
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

5.  Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.

Authors:  I Aidonidis; J Brachmann; I Rizos; A Zacharoulis; I Stavridis; P Toutouzas; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.